Psilocybin（Pilz Bioscience）

N/A

Report date: 2024/06/07 13:37:33
NME

Base Information

Drug NamePsilocybin（Pilz Bioscience）
Drug Alias NameNM-1001NM-1010PLZ-1013
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1a (5-HT1a) receptor agonistsSerotonin 2a (5-HT2a) receptor agonists
TargetsSerotonin 1a (5-HT1a) receptorSerotonin 2a (5-HT2a) receptor
Therapy Area/IndicationsCognitive DysfunctionDepressive Disorder, Treatment-ResistantBehavior +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesPilz Bioscience Corp
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of North Carolina At Chapel Hill
Inactive CompaniesNova Mentis Life Science Corp
Active IndicationsDepressive Disorder, Treatment-Resistant
Inactive IndicationsCognitive DysfunctionBehaviorFragile X Syndrome

Other Information

ATC CodeN/A
Related LinksN/A